See What HealthDay Can Do For You
Contact Us

Hematologic Markers Predict Nasopharyngeal Cancer Survival

High neutrophil-lymphocyte, platelet-lymphocyte ratios tied to shorter survival

TUESDAY, Sept. 22, 2015 (HealthDay News) -- Pretreatment neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be predictors for survival in nasopharyngeal carcinoma, according to a study published online Sept. 11 in Head & Neck.

Wei Sun, M.D., from the Huazhong University of Science and Technology in Wuhan, China, and colleagues evaluated the prognostic significance of various hematologic parameters in 251 patients with nasopharyngeal carcinoma.

The researchers found that NLR ≥2.7 (hazard ratio, 2.01; P = 0.005) and PLR ≥167.2 (hazard ratio, 2.12; P = 0.001) were significantly associated with shorter progression-free survival, while PLR ≥163.4 was correlated with poor overall survival (hazard ratio, 2.64; P = 0.011).

"Pretreatment NLR and PLR can be independent prognostic factors for patients with NPC," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.